以嶺藥業跌超5% 連花清瘟膠囊有上百種替代藥
格隆匯12月13日丨以嶺藥業高位回落,盤中一度跌超5%,該股自9月底以來,從18.82元上漲近日53.96元新高,期間累漲186%。有消息稱工信部商請各地委託生產連花清瘟產品。此外,武漢市市場監管局強調,一些藥品出現了一盒難求和漲價的現象。其實,可替代品種有很多。以連花清瘟為例,類似的中成藥還有上百種。因此,不需要拘泥於某個單一藥物,其他很多中成藥如金銀花、金花清感、柴胡口服液、清熱解毒口服液等也可以選用,消費者可到藥店感冒藥專櫃選擇或由藥師推薦代替用藥品種。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.